After years of research and development, we have a balanced and diversified product pipeline with a strategic focus on major cancers and other AR related diseases.

      mCRPC: Metastatic Castration-Resistant Prostate Cancer

      MRCT: Multi-Regional Clinical Trial

      TNBC: Triple Negative Breast Cancer

      HCC：Hepatocellular Carcinoma

      BCC: Basal Cell Carcinoma

      PROTAC = proteolysis targeting chimera

* Represents a potential first-in-class drug candidate for the relevant indication 

^Expect to file IND in 4Q